Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2023 | 392 | 5.040 |
Why?
|
| Mastectomy | 15 | 2023 | 34 | 3.190 |
Why?
|
| Surgeons | 8 | 2023 | 78 | 2.540 |
Why?
|
| Organ Sparing Treatments | 2 | 2020 | 11 | 1.250 |
Why?
|
| Mastectomy, Segmental | 8 | 2023 | 29 | 1.210 |
Why?
|
| Nipples | 4 | 2021 | 5 | 1.150 |
Why?
|
| Ergonomics | 3 | 2021 | 6 | 0.970 |
Why?
|
| Mammaplasty | 3 | 2023 | 6 | 0.920 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2021 | 1 | 0.710 |
Why?
|
| Mammography | 1 | 2019 | 42 | 0.590 |
Why?
|
| Female | 25 | 2023 | 12958 | 0.580 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 97 | 0.560 |
Why?
|
| Phyllodes Tumor | 1 | 2017 | 2 | 0.550 |
Why?
|
| Rare Diseases | 1 | 2017 | 12 | 0.550 |
Why?
|
| Humans | 27 | 2023 | 22958 | 0.480 |
Why?
|
| Quality of Life | 2 | 2019 | 559 | 0.450 |
Why?
|
| Middle Aged | 13 | 2023 | 7911 | 0.310 |
Why?
|
| Surgical Oncology | 2 | 2019 | 6 | 0.290 |
Why?
|
| Pilot Projects | 2 | 2019 | 370 | 0.280 |
Why?
|
| Prospective Studies | 3 | 2021 | 1493 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 235 | 0.270 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 356 | 0.230 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 31 | 0.230 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 22 | 0.220 |
Why?
|
| Prognosis | 4 | 2019 | 730 | 0.220 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 62 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 11 | 0.190 |
Why?
|
| Breast Implants | 2 | 2019 | 5 | 0.190 |
Why?
|
| Breast Neoplasms, Male | 1 | 2022 | 11 | 0.190 |
Why?
|
| Adult | 8 | 2023 | 6927 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2019 | 117 | 0.180 |
Why?
|
| Operating Rooms | 1 | 2021 | 12 | 0.180 |
Why?
|
| Workload | 1 | 2021 | 26 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1412 | 0.170 |
Why?
|
| Oncologists | 1 | 2021 | 2 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 27 | 0.170 |
Why?
|
| Burnout, Professional | 1 | 2021 | 26 | 0.170 |
Why?
|
| Contraindications, Procedure | 1 | 2020 | 2 | 0.160 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 26 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2019 | 7 | 0.150 |
Why?
|
| Acellular Dermis | 1 | 2019 | 6 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 39 | 0.150 |
Why?
|
| Breast Implantation | 1 | 2019 | 3 | 0.150 |
Why?
|
| Radiologists | 1 | 2019 | 8 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2019 | 29 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 52 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 62 | 0.150 |
Why?
|
| Intraoperative Care | 1 | 2019 | 40 | 0.150 |
Why?
|
| Radiation Oncology | 1 | 2019 | 14 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 107 | 0.150 |
Why?
|
| Operative Time | 1 | 2019 | 82 | 0.150 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 153 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2018 | 33 | 0.140 |
Why?
|
| Decision Making | 1 | 2019 | 176 | 0.140 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 9 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 240 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 200 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 109 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 26 | 0.120 |
Why?
|
| Aged | 8 | 2023 | 7448 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 77 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 40 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 56 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 50 | 0.110 |
Why?
|
| Neoplasms | 1 | 2017 | 216 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2019 | 2994 | 0.110 |
Why?
|
| Pain | 1 | 2017 | 332 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2017 | 219 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 135 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 164 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 1020 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 760 | 0.100 |
Why?
|
| Young Adult | 3 | 2023 | 1651 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2016 | 811 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 539 | 0.080 |
Why?
|
| Rosaniline Dyes | 1 | 2008 | 2 | 0.070 |
Why?
|
| Radioisotopes | 1 | 2008 | 13 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 88 | 0.070 |
Why?
|
| Adolescent | 2 | 2023 | 1881 | 0.070 |
Why?
|
| United States | 2 | 2021 | 1765 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 1262 | 0.050 |
Why?
|
| Self Concept | 1 | 2023 | 37 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2023 | 46 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 31 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2019 | 548 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2023 | 134 | 0.050 |
Why?
|
| Male | 3 | 2022 | 12466 | 0.040 |
Why?
|
| Emotions | 1 | 2021 | 69 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 1417 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 143 | 0.040 |
Why?
|
| Video Recording | 1 | 2019 | 28 | 0.040 |
Why?
|
| Fear | 1 | 2019 | 45 | 0.040 |
Why?
|
| Body Image | 1 | 2019 | 27 | 0.040 |
Why?
|
| Esthetics | 1 | 2019 | 11 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 43 | 0.040 |
Why?
|
| Patient Preference | 1 | 2019 | 33 | 0.040 |
Why?
|
| Carcinoma, Lobular | 1 | 2019 | 22 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 82 | 0.040 |
Why?
|
| Pectoralis Muscles | 1 | 2019 | 16 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 3728 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2019 | 82 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 110 | 0.040 |
Why?
|
| Consensus | 1 | 2019 | 81 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2019 | 107 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2019 | 50 | 0.040 |
Why?
|
| Wound Healing | 1 | 2019 | 108 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 268 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 202 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 58 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 309 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 311 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 256 | 0.030 |
Why?
|
| Needles | 1 | 2016 | 18 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 387 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1046 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 414 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2018 | 190 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 638 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 295 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 860 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 362 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2016 | 2941 | 0.020 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 6 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2008 | 14 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 124 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 228 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 193 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 442 | 0.020 |
Why?
|